Top Markets
Coin of the day
Taro Pharmaceutical Industries Ltd. Taro Pharmaceutical Industries Ltd.

Taro Pharmaceutical Industries Ltd.

TARO
Kedudukan dalam Saham #7354
Taro Pharmaceutical Industries Ltd. operates as a scientifically-driven... Taro Pharmaceutical Industries Ltd. operates as a scientifically-driven pharmaceutical enterprise, specializing in the development, manufacturing, and commercialization of both prescription and over-the-counter medications. Its market reach spans the United States, Canada, Israel, and various other international territories. The company also produces active pharmaceutical ingredients (APIs), primarily for integration into its own finished dosage form products. Its extensive product catalog addresses a broad spectrum of medical conditions and therapeutic areas, encompassing treatments for allergies, pain (analgesic), bacterial and fungal infections (antibacterial, antibiotic, antifungal), seizures (anticonvulsant), nausea (antiemetic), inflammation (anti-inflammatory), cancer (anti-cancer, topical anti-neoplastic), blood clot prevention (antiplatelet agent), fever reduction (antipyretic), cardiovascular issues, central nervous system disorders, hormonal regulation (corticosteroid, endocrine), cosmetic applications, coughs and colds, dermatological complaints, fluid management (diuretic), gastrointestinal problems, constipation (laxative), severe pain (narcotics), neuropathic pain, neuropsychiatric conditions, and sleep/anxiety management (sedative/hypnotic). These pharmaceutical goods are available in numerous formats, including capsules, creams, drops, emulsions, gels (and gel kits), granules, injectables, lotions, oils, ointments, pastes, powders (and powders for solution), rectal suppositories, shampoos, solutions (and solutions for infusion), sprays, suspensions, syrups, tablets, toothpastes and mouthwashes, topical foams, and topical solutions. Taro distributes and sells its products directly to a wide array of clients, such as pharmaceutical wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, other direct purchasers, and various healthcare institutions and private pharmacies. The company was established in 1950, with its main offices situated in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a wholly-owned subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.
Harga Saham
$42.98
Disegerakkan terakhir: 2024-06-21
Modal Pasaran
$1.62B
Perubahan (1 hari)
0.01%
Perubahan (1 tahun)
0.00%
Negara
IL
Perdagangan Taro Pharmaceutical Industries Ltd. (TARO)

Kategori

Nisbah P/E bagi Taro Pharmaceutical Industries Ltd. (TARO)
Nisbah P/E pada August 2026 TTM: 30.05
Menurut laporan kewangan dan harga saham terkini Taro Pharmaceutical Industries Ltd., nisbah P/E semasa (TTM) ialah 30.05. Pada akhir 2023, syarikat mempunyai nisbah P/E sebanyak 35.92.
Sejarah nisbah P/E bagi Taro Pharmaceutical Industries Ltd. dari 1999 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) 30.05 1.98%
2024 29.47 -17.98%
2023 35.92 28.54%
2022 27.95 -497.43%
2021 -7.03 -172.97%
2020 9.64 -36.03%
2019 15.07 -19.08%
2018 18.62 76.40%
2017 10.55 -6.95%
2016 11.34 -9.07%
2015 12.47 -8.53%
2014 13.64 38.57%
2013 9.84 52.53%
2011 6.45 -29.15%
2010 9.11 198.06%
2009 3.06 -69.11%
2008 9.89 27.00%
2007 7.79 -319.39%
2006 -3.55 -104.93%
2005 71.98 -19.62%
2004 89.55 194.34%
2003 30.42 25.42%
2002 24.26 -32.60%
2001 35.99 8.92%
2000 33.04 25.29%
1999 26.38 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.